22 results about "Inner membrane" patented technology

The application provides an engineered probiotic with intracellular chimeric nanoscale enzyme, which is a probiotic modified with several antioxidant enzymes on an inner membrane; the antioxidant enzyme is composed of a metal oxide nanoscale enzyme with a particle size less than 10 nm and a targeting molecular structure and a saccharide molecular structure modified on the surface of the metal oxide nanoscale enzyme; the targeting molecular structure and the saccharide molecular structure are connected to the surface of the metal oxide nanoscale enzyme through a connecting group containing a metal ligand structure based on coordination and electrostatic interaction, and the antioxidant enzyme accounts for 5-20% of the mass of the engineered probiotic. The application also provides a method for preparing the engineered probiotic and application of the engineered probiotic in preparation of a medicine or food for preventing or treating antibiotic-associated diarrhea. The engineered probiotic can realize efficient elimination of hydroxyl radicals near a membrane induced by an antibiotic, so as to accurately inhibit a lipid peroxidation reaction and protect the integrity of a cell membrane.

A device for activating the mitochondrion, wherein negative charge and reactive oxygen are delivered from outside to the mitochondrion via a negative charge and reactive oxygen delivery unit to serve as material for the mitochondrial redox reaction; and, wherein a calcium ion channel stimulation unit can stimulate an in vivo calcium ion to transport a protein across a calcium ion on an inner membrane of the mitochondrion into a matrix space of the mitochondrion, whereby an influx of the calcium ion promotes the depolarization of the mitochondrion and increases the activity of mitochondrial oxidative phosphorylation.

Provided are a recombinant Escherichia coli with improved ability to secrete extracellular endoglucanase (BcsZ) and a construction method therefor. The recombinant Escherichia coli is constructed by using Escherichia coli JBZ-DH5α as a starting strain and inserting a membrane protein coding gene. The membrane protein gene is one of the following coding genes: a coding gene of zinc transporter permease znuB, a coding gene of DUF1449 family inner membrane protein ylaC, and a coding gene of UPF0410 family inner membrane protein ymgE.

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrate into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, revitalizing cells, modulating T cell function, improving feed efficiency, prolonging lifespan and treating cancer.

The problem to be solved by the present invention is to provide more and better options for treating any solid tumor with high frequency microsatellite instability (high frequency MSI or MSI-H) alterations, cervical cancer, endometrial cancer, lung cancer, brain cancer and breast cancer.SOLUTION: The present invention relates to multispecific antibodies comprising an antigen binding site that binds an extracellular part of CD137 and an antigen binding site that binds an extracellular part of a second membrane protem for use in a method of treatment of cancers in a subject in need thereof. The invention further relates to such multispecific antibodies, as well as methods and other aspects related thereto.SELECTED DRAWING: None

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

Systems for determining COVID include a protein biosensor that interacts with human biological sample and outputs the first and second signals; a wireless communication device; a memory device with detectors integrated into the memory device. The protein biosensor is configured to use two different biological components separated by an internal membrane within the protein biosensor. The concentration of the first biological component is the limit concentration for the first virus strain and the concentration of the second biological component is the limit concentration for the second virus strain. The memory device is configured to receive the first and second signals and set the first and second signal thresholds for each integrated detector. The memory device identifies the presence of the first or second virus strain in response to integrated detectors are detecting a value that is greater than or less than the first or second signal threshold.

The application discloses a kind of nano preparation for treating ischemia-reperfusion injury and its preparation method and application, belong to the field of pharmaceutical preparation, the nano preparation includes active ingredient, albumin, liposome phospholipid bilayer and target head, active ingredient is composed of antioxidant and coenzyme Q10 and its analog, liposome phospholipid bilayer is composed of phospholipid, cholesterol and DSPE-mPEG 2000 Composition, the nano preparation can both remove active oxygen produced in cell and relieve intracellular oxidative stress, also can enter mitochondrial inner membrane and help mitochondrial respiratory chain electron transfer, repair damaged mitochondrial function, reduce the generation of active oxygen from root, so as to play the effect of treating both symptoms and root cause.The application proposes a kind of new strategy for treating ischemia-reperfusion injury related diseases, by removing active oxygen, effectively restoring blocked electron transport chain, improving the antioxidant capacity of cell itself, reducing oxidative damage caused by ferroptosis, with good practical application prospect.

The invention belongs to the technical field of biomimetic materials, and particularly relates to a gold nanomaterial positively coated with a cell membrane as well as a preparation method and application of the gold nanomaterial. The cell membrane forward coated gold nanomaterial comprises a gold nanomaterial and a cell membrane layer coated on the surface of the gold nanomaterial, the inner membrane of the cell membrane layer faces the gold nano material, and the cell membrane layer is connected with the gold nano material through biotin-streptavidin non-covalent bonding. Selectively modifying biotin in the cell endomembrane by using the membrane fusion spherical nucleic acid, and extracting to obtain an endomembrane biotinylated cell membrane; the preparation method comprises the following steps: co-incubating a streptavidin functionalized gold nanomaterial and a cell membrane, and realizing forward ordered coating of the cell membrane through biotin-streptavidin specific binding. The material prepared by the invention has the characteristics of simple preparation method, mild conditions, ordered cell membrane coating and high coating rate. The cell membrane forward coated nano material can be used for targeted delivery of drugs to realize precise diagnosis and treatment of cancers.

The invention discloses an HlyA secretion system for increasing the secretion amount of substrate protein and a construction method and application thereof.The HlyA secretion system comprises a first component, a second component and a third component, the first component comprises an inner membrane transporter HlyB and a membrane interstitial adaptor protein HlyD, and the inner membrane transporter HlyB and the membrane interstitial adaptor protein HlyD are obtained by expressing modified hlyBD operons; according to the modified hlyBD operon, a nucleotide sequence for coding a hexa-polyhistidine tag is inserted behind an hlyD gene initiation codon in the hlyBD operon; and a second component: an outer membrane channel protein TolC derived from a host cell. According to the invention, the HlyD protein is specifically modified, so that the secretion amount of the HlyA secretion system to the substrate protein is obviously increased.

The utility model relates to the technical field of storage water tank, concretely relates to a full-closed storage water tank, including the shell, be provided with soft inner membrane in the shell, be provided with the air pressure balance subassembly of intercommunication with the inner wall of shell on the shell, the top of soft inner membrane is provided with the water inlet pipe of intercommunication with soft inner membrane inside, the bottom of soft inner membrane is provided with the water outlet pipe of intercommunication with soft inner membrane inside. With the help of soft inner membrane to store water, when water, soft inner membrane along with the increase of water, volume becomes big, at the same time with the help of air pressure balance subassembly to discharge the extra air in the shell, when water, soft inner membrane along with the reduction of water, volume becomes small, at the same time with the help of air pressure balance subassembly to fill in the air. The whole water and water outlet process, air only exists between the shell and soft inner membrane, will not enter the soft inner membrane inside and contact with water, like this can effectively avoid the oxidation reaction or the problem of bacteria breeding after air and water contact.

The invention discloses an oxygen enrichment membrane assembly and an oxygen enrichment machine, the oxygen enrichment membrane assembly comprises a shell and a membrane layer, the membrane layer is an oxygen enrichment membrane, a mounting cavity is formed in the shell, the membrane layer is arranged in the mounting cavity of the shell, and the membrane layer is connected with the shell and divides the mounting cavity into a membrane inner cavity and a membrane outer cavity; a first vent hole and a second vent hole which are communicated with the membrane outer cavity are formed in the shell, and an airflow channel flowing through the outer surface of the membrane layer is formed between the first vent hole and the second vent hole, so that nitrogen molecules attached to the outer surface of the membrane layer are discharged out of the membrane outer cavity along the airflow channel; the membrane inner cavity is communicated with a negative pressure device in a sealed mode, and the negative pressure device is used for driving air to enter the membrane inner cavity from the membrane outer cavity through the membrane layer. The airflow channel flowing through the outer surface of the membrane layer is formed between the first vent hole and the second vent hole which are communicated with the outside of the membrane, nitrogen molecules attached to the outer surface of the membrane layer are discharged through airflow of the airflow channel, and the situation that the oxygen separation efficiency is reduced due to the fact that the nitrogen molecules block the membrane layer is avoided.

The application discloses a Parkinson's disease targeted application of a pueraria exosome loaded with a mitochondria-activated miRNA, and belongs to the field of biological applications.The miRNA comprises at least one of miRNAs shown in sequences as shown in SEQ ID No, 1 to SEQ ID No, 23.The pueraria exosome and the miRNA delivered thereby in the application show a good treatment effect on Parkinson's disease, and mainly play a role in improving mitochondrial dysfunction, such as promoting mitochondrial autophagy, improving mitochondrial membrane potential, reducing oxidative stress, maintaining the integrity of the mitochondrial inner membrane respiratory chain, and increasing ATP generation.The application further discloses a delivery scheme of the pueraria-derived exosome as the miRNA carrier by using neuron-targeted modification, which can improve the targeting and stability of the miRNA, and overcome the problems of low miRNA drug delivery efficiency and easy degradation.The application is expected to promote the treatment process of Parkinson's disease through the neuron-targeted pueraria exosome and the miRNA delivered thereby.

The invention discloses hydrogel microspheres for inhibiting mitochondrial DNA release and improving osteoarthritis and application, and aims at the clinical dilemma that early and middle-stage osteoarthritis lacks specific treatment, the invention discovers that mechanical overload induced mitochondrial membrane potential reduction (from-180mV to-100mV) leads to abnormal opening of VDAC, miMOMP change and mtDNA outleakage, and the hydrogel microspheres can inhibit mitochondrial DNA release and improve osteoarthritis. The method is a key mechanism for steady-state imbalance of cartilage cells. On the basis, a Fe / BiOCl (at) AHAMA-GelMA dual response system is constructed, wherein the Fe / BiOCl nanosheet has positive charges (+ 25-30 mV) in a resting state and can target a mitochondrial inner membrane, and local negative potential (about-50 mV) is generated under mechanical stimulation to release electrons to recover membrane potential; the AHAMA-GelMA hydrogel microspheres are combined with amino groups on the surface of cartilage through aldehyde groups to realize spatial positioning, and a targeted mechanical overload area is recognized by utilizing the specificity of MMPs to gelatin. In-vivo and in-vitro experiments prove that the system can convert overload abnormal stress into repair electric energy, inhibit mtDNA outleakage, remarkably improve the mitochondrial function and relieve cartilage degeneration, and a new disease modification treatment strategy is provided for osteoarthritis.

The invention belongs to the technical field of medicines, and particularly relates to ROS (reactive oxygen species) double-response nanoparticles for co-delivery of metabolic inhibitors and immune activators as well as a preparation method and application of the ROS double-response nanoparticles. The nanoparticles comprise a phenylboronic acid ester modified polymer which responds to ROS cracking, a ferrocene modified polymer which responds to ROS catalytic Fenton reaction, S-Gboxin which inhibits mitochondrial ATP synthesis, and a TGF-beta inhibitor Galunissertib which regulates immunity. The nanoparticles are targeted to Glut1 through DHA to mediate tumor targeting, and after entering tumor tissues and incorporating cells, the nanoparticles respond to ROS phenylboronic acid ester splitting decomposition, and drug release is accelerated; and under the catalysis of ferrocene, the common ROS in the tumor cells is converted into the superoxide compound with higher oxidation capacity. The released S-Gboxin is combined with the inner membrane of mitochondria, so that the membrane potential is reduced, and the tumor energy supply is inhibited. Similarly, the Galunissertib down regulates the tumor microenvironment TGF-beta, inhibits the expression of proteins pSMAD2 / 3 and TSP-1, and remodels the immunosuppressive microenvironment.

The application discloses a lysosome-internal calcium and other ion detection probe, a preparation method and application thereof. Through a large amount of optimization and screening on a probe targeting property, an optimal lysosome positioning signal is determined, a fluorescent probe capable of realizing lysosome inner membrane positioning and truly reflecting changes of ions (especially calcium ions) in the lysosome and a small molecule dye targeting loading strategy are first constructed, the lysosome targeting efficiency is improved, and the interference of probe molecular weight reduction on the physiological function of the lysosome is greatly reduced. Meanwhile, the probe has the advantages of high acid environment stability, accurate subcellular positioning, high sensitivity and high specificity, so that the universality of the probe is extremely strong, and the probe can realize detection on different types of chemical synthesis small molecule dyes in the lysosome.

This invention relates to the field of nanomedicine technology and discloses the application of nano-Amy@NPs-MM / PL1 in the treatment of endometriosis. The nano-Amy@NPs-MM / PL1 comprises a nanocarrier PEG-PLGA, a nanomedicine Amy, a nano-coated macrophage membrane, and a targeting peptide PL1. The steps are: S1, macrophage membrane extraction: using a cell membrane extraction kit, macrophage membranes are separated; S2, targeting peptide insertion into the macrophage membrane: the targeting peptide PL1 is inserted into the macrophage membrane to obtain the targeting macrophage membrane MM / PL1; S3, preparation of PEG-PLGA-loaded Amy. This invention demonstrates that Amy@NPs-MM / PL1 inhibits the activation of the TNF-α / TNFR1 / NF-κB signaling pathway, blocks the downstream caspase-1 / GSDMD-mediated pyroptosis cascade, reduces the release of inflammatory factors, and inhibits angiogenesis and the expression of invasive factors. It achieves multi-level intervention from anti-oxidation and anti-pyroptosis to neuroprotection and metabolic regulation, providing a new strategy with both theoretical innovation and clinical translational potential for the comprehensive treatment of endometriosis.

The invention discloses a mitochondrial targeting type viscosity fluorescent probe as well as a synthesis method and application thereof, and belongs to the technical field of biological materials. The chemical structure of the probe is shown as a formula I. The mitochondrial targeting viscosity fluorescent probe provided by the invention targets a mitochondrial inner membrane, structurally comprises a twisted intramolecular charge transfer (TICT) fluorescent rotor, and can emit a fluorescence signal with adjustable intensity along with the change of microenvironment viscosity. Compared with the traditional mitochondrial dye, the probe does not depend on mitochondrial membrane potential, and has excellent light stability and ultrahigh resolution imaging capability. Cell experiments show that the probe can be used for Alzheimer's disease (AD) imaging, and can indicate mitochondrial inner membrane viscosity change in real time and reveal a dynamic process of interaction between mitochondria and lysosome; pathological characteristics such as mitochondrial viscosity increase, ridge structure disorder, network fragmentation and lysosomal dyskinesia are observed in an AD model.

The application provides a vesicle with a double-layer membrane structure, which comprises an outer membrane and an inner membrane, the outer membrane comprises a film forming agent and an inducer, the inner membrane comprises a film forming agent and an inducer, the vesicle further comprises an active substance, the active substance is located inside the inner membrane, and stable and efficient wrapping of the active substance can be realized through film forming agent and double-layer membrane inducer proportion selection.

The invention provides a method for activating granulate bodies, which mainly comprises the following steps of: supplying negative charges and active oxygen to the granulate bodies from the outside through a negative charge and active oxygen supply unit so as to serve as raw materials for redox of the granulate bodies; the calcium ion channel promoting unit promotes the calcium ions in the body to enter the matrix space of the granulonema through calcium transport proteins on the granulonema inner membrane, so that the internal flow of the calcium ions can promote the depolarization of the granulonema, and the oxidative phosphorylation activity of the granulonema is improved. Thus, granulocyte activation and ATP production are enhanced.

The invention relates to mitochondrial targeting double-response composite hydrogel and a preparation method thereof. The preparation method comprises the following steps: synthesizing cationic amylose; preparing a compound; preparation of grafted triphenylphosphine and a composite hydrogel; according to the invention, the amylose is grafted with the TPP and protects the FGF21 structure, the amylose not only solves the problem of sudden release of the TPP, but also anchors the BPQDs in a micelle shell layer, so that the photo-thermal effect is closer to mitochondria, and the activity of the FGF21 is obviously protected. In addition, triple effects of photo-thermal, FGF21 signal regulation and mitochondrial targeting are combined for local implantation treatment of endometriosis for the first time, and almost complete fading of deep ectopic lesions can be realized.

The present application relates to a kind of nanoparticles for preventing endometrial heterotopia and preparation method thereof, belong to biological medicine technical field.The present application provides a kind of nanoparticles, this nanoparticle includes bacterial outer membrane vesicle (OMV) and polylactic acid-glycolic acid copolymer (PLGA), wherein, bacterial outer membrane vesicle is wrapped in polylactic acid-glycolic acid copolymer surface.The present application will be wrapped in the surface of PLGA core OMV, retains its biological characteristics, imitates bacteria and presents antigen to immune system.Simultaneously, PLGA core provides a series of controllable physical and chemical properties (such as particle size and formation), so that the size of synthesized OMV-PLGA is more uniform.In addition, PLGA provides a hard core for OMV membrane, so that OMV-PLGA can more effectively pass through cell membrane than OMV, to improve the uptake efficiency of cell.